Deazapurines and uses thereof

Details Deazapurines and uses thereof Deazapurines and uses thereof

2008-01-01

2008-01-01

Andres, Janet (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

10500840

ABSTRACT:
The present invention provides compounds having formula (I), wherein R1, R2, R3and n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally

REFERENCES:
patent: 3891660 (1975-06-01), Denzel et al.
patent: 4891374 (1990-01-01), Thorwart et al.
patent: 5342832 (1994-08-01), Siren
patent: 5360794 (1994-11-01), Arora
patent: 5486525 (1996-01-01), Summers et al.
patent: 5492915 (1996-02-01), Dereu et al.
patent: 5506238 (1996-04-01), Miyake et al.
patent: 5565452 (1996-10-01), Arndts et al.
patent: 5632991 (1997-05-01), Gimbrone, Jr.
patent: 5654305 (1997-08-01), Shepard et al.
patent: 5656654 (1997-08-01), Buzzetti et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5981536 (1999-11-01), Mullner et al.
patent: 6143743 (2000-11-01), Wilde et al.
patent: 6410516 (2002-06-01), Baltimore et al.
patent: 6521654 (2003-02-01), Wehner et al.
patent: 6599741 (2003-07-01), Hecker et al.
patent: 6831065 (2004-12-01), May et al.
patent: RE39464 (2007-01-01), Cook et al.
patent: 2006/0194833 (2006-08-01), Chase et al.
patent: 0434405 (1991-06-01), None
patent: 0 945 422 (1999-09-01), None
patent: 0 945 443 (1999-09-01), None
patent: 0 399 731 (2001-07-01), None
patent: 1 256 582 (2002-11-01), None
patent: WO 99/01454 (1999-01-01), None
patent: WO 99/65909 (1999-12-01), None
patent: WO 00 76505 (2000-12-01), None
patent: WO 01/00610 (2001-01-01), None
patent: WO 01/30774 (2001-05-01), None
patent: WO 01/30778 (2001-05-01), None
patent: WO 01/30778 (2001-05-01), None
patent: WO 01/58900 (2001-08-01), None
Krenitsky et al, Imidazo[4,5-c]pyridines (3-Deazapurines) and Their Nucleosides as Immunosuppressive and Antiinflammatory Agents, J. Med. Chem. 1986, 29, 138-143.
International Search Report for PCT/US03/00366.
Abrahamsen, et al., “Cytokines and Bone Loss in a 5-Year Longitudinal Study—Hormone Replacement Therapy Suppresses Serum Soluble Interlukin-6 Receptor and Increases Interleukin-1-Receptor Antagonist: The Danish Osteoporosis Prevention Study”Journal of Bone and Mineral Research: 15 (8): 1545-1554, 2000.
Azuma, et al., “Tumor Necrosis Factor-α Induces Differentiation of and Bone Resorption by Osteoclasts”Journal of Biological Chemistry275(7): 4858-4864, 2000.
Cain, et al., “p-38 MAPK Inhibition Decreases TNF-α Production and Enhances Postischemic Human Myocardial Function”Journal of Surgical Research83 (1): 7-12, 1999.
Koyano, et al., “Effects of FR167653 on Ischemia-reperfusion Injury: Evaluation Through Preservation and Transplantation in Canine Hearts”J. Heart Lung Transplant17 (12): 1247-54, 1998.
Souza, et al., “Effects of Inhibition of PDE4 and TNF-α On Local And Remote Injuries Following Ischaemia And Reperfusion Injury”British Journal of Pharmacology134 (5): 985-994, 2001.
Abrahamsen, et al., “Cytokines and Bone Loss in a 5-Year Longitudinal Study—Hormone Replacement Therapy Suppresses Serum Soluble Interlukin-6 Receptor and Increases Interleukin-1-Receptor Antagonist: The Danish Osteoporosis Prevention Study”Journal of Bone and Mineral Research15: 1545-1554, 2000.
Cain, et al., “p-38 MAPK Inhibition Decreases TNF-α Production and Enhances Postischemic Human Myocardial Function”Journal of Surgical Research83: 7-12, 1999.
Koyano, et al., “Effects of FR167653 on Ischenia-reperfusion Injury: Evaluation Through Preservation and Transplantation in Canine Hearts”J. Heart Lung Transplant17: 1247-54, 1998.
Souza, et al., “Effects of Inhibition of PDE4 and TNF-α On Local And Remote Injuries Following Ischaemia And Reperfusion Injury”British Journal of Pharmacology134: 985-994, 2001.
International Search Report for Related International Application No. PCT/US2004/000293, Aug. 13, 2007.
Yusuf-Makagiansar et al. “Inhibition of LFA-1/ICAN-1 and VLA-4/VCAM-1 as a Therapeutic Approach to Inflammation and Autoimmune Diseases”,Med. Res. Rev.22(2):146-167 (2002).
Norton et al. “Expression of adhesion molecules in human intestinal graft-versus-host disease”,Clin. Exp. Immunol.87:231-236 (1992).
Brodt et al. “Liver Endothelial E-Selectin Mediates Carcinoma Cell Adhesion and Promotes Liver Metastasis”,Int. J. Cancer71:612-619 (1997).
Finzel et al. “ICAM-1 supports adhesion of human small-cell lung carcinoma to endothelial cells”,Clin. and Exp. Metastasis21:185-189 (2004).
Rosette et al. “Role of ICAM1 in invasion of human breast cancer cells”,Carcinogenesis26(5):943-950 (2005).
Tak et al. “NF-kB: a key role in inflammatory diseases”,J. Clin. Investigation107(1):7-11 (2001).

Affiliated with

Also associated with

Rating

Deazapurines and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Deazapurines and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Deazapurines and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3937646